Search in:

OncoTargets and Therapy Volume 10, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Ittai B Muller1 Department of Clinical Chemistry

Adrianus J de Langen2 Department of Pulmonology, VU University Medical Center;3 Department of Thoracic Oncology, Netherlands Cancer Institute

Elisa Giovannetti4 Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands;5 Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy

Godefridus J Peters4 Department of Medical Oncology, VU University Medical Center, Amsterdam, the NetherlandsCorrespondence[email protected]

Pages 4535-4541 | Published online: 13 Sep 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (19)

Zizong Wang, Yushuai Han, Houquan Tao, Mengxiang Xu, Zhengchuang Liu, Jianhua Zhu, Wei Li, Jie Ma, Zhifang Liu, Weiran Wang & Tonghui Ma. (2022) Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer . Molecular Oncology 17:5, pages 765-778.
Crossref

Parteek Prasher, Mousmee Sharma, Yinghan Chan, Sachin Kumar Singh, Krishnan Anand, Harish Dureja, Niraj Kumar Jha, Gaurav Gupta, Flavia Zacconi, Dinesh K. Chellappan & Kamal Dua. (2023) Recent Trends in Rationally Designed Molecules as Kinase Inhibitors. Current Medicinal Chemistry 30:13, pages 1529-1567.
Crossref

Gabriela Bordeianu, Nina Filip, Andrei Cernomaz, Bogdan Veliceasa, Loredana Liliana Hurjui, Alin Constantin Pinzariu, Mihaela Pertea, Andreea Clim, Mihai Vasile Marinca & Ionela Lacramioara Serban. (2023) The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. Biomedicines 11:3, pages 705.
Crossref

Yichu Nie, Fenglan Feng, Wei Luo, Andrew J. Sanders, Yidi Zhang, Jiaming Liang, Cheng Chen, Weineng Feng, Weiquan Gu, Weiping Liao, Wei Wang, Jinfeng Chen, Lijian Zhang, Wen G. Jiang & Jin Li. (2022) Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting. Cancer Gene Therapy 29:10, pages 1405-1417.
Crossref

Junjun Li, Yongchang Zhang, Li Wang, Min Li, Jianbo Yang, Pan Chen, Jie Zhu, Xiayu Li, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, James B. McCarthy, Bo Xiang & Mei Yi. (2022) FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma. Cell Death & Disease 13:8.
Crossref

Ye Tian, Liguo Guan, Yuting Qian, Yue Wu & Zexin Gu. (2022) Effect of PPP1R14D gene high expression in lung adenocarcinoma knocked out on proliferation and apoptosis of DMS53 cell. Clinical and Translational Oncology 24:10, pages 1914-1923.
Crossref

Zhihao Wang, Kidane Siele Embaye, Qing Yang, Lingzhi Qin, Chao Zhang, Liwei Liu, Xiaoqian Zhan, Fengdi Zhang, Xi Wang & Shenghui Qin. (2021) Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma. Aging 13:14, pages 18701-18717.
Crossref

Dung-Tsa Chen, Wenyaw Chan, Zachary J. Thompson, Ram Thapa, Amer A. Beg, Andreas N. Saltos, Alberto A. Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor A. Rose & Ben Creelan. (2021) Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLOS ONE 16:7, pages e0252041.
Crossref

Yan Zhang, Yaping Qin, Hongen Xu, Qihui Yao, Yalan Gao, Yushu Feng & Jingli Ren. (2021) Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib. Pathology and Oncology Research 27.
Crossref

Zhenyang Lv & Ting Lei. (2020) Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters. BMC Cancer 20:1.
Crossref

Shiwang Wen, Lei Dai, Lei Wang, Wenjian Wang, Duoguang Wu, Kefeng Wang, Zhanghai He, Aodi Wang, Hui Chen, Peng Zhang, Xiaowei Dong, Yu-An Dong, Kai Wang, Ming Yao & Minghui Wang. (2019) Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. The Oncologist 24:11, pages e1070-e1081.
Crossref

Jakub Hofman, Ales Sorf, Dimitrios Vagiannis, Simona Sucha, Eva Novotna, Sarah Kammerer, Jan-Heiner Küpper, Martina Ceckova & Frantisek Staud. (2019) Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition 47:7, pages 699-709.
Crossref

Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo & Yingliang Wu. (2019) Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. RSC Advances 9:31, pages 17921-17932.
Crossref

Arthur Aubry, Stéphane Galiacy & Michèle Allouche. (2019) Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. Cancers 11:3, pages 275.
Crossref

E. V. Reutova & K. K. Laktionov. (2019) New opportunities in the treatment of patients with ALK-positive non-small cell lung cancer. Onkologiya. Zhurnal imeni P.A.Gertsena 8:3, pages 226.
Crossref

Daniel de Klerk, Richard Honeywell, Gerrit Jansen & Godefridus Peters. (2018) Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers 10:12, pages 503.
Crossref

Masahiro Yamasaki, Wakako Daido, Kunihiko Funaishi, Kazuma Kawamoto, Yu Matsumoto, Naoko Matsumoto, Masaya Taniwaki, Nobuyuki Ohashi & Noboru Hattori. (2018) Nivolumab therapy for lung cancer with tracheo-parenchymal fistula. Medicine 97:50, pages e13739.
Crossref

Song Xu, Renwang Liu & Yurong Da. (2018) Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma. Thoracic Cancer 9:8, pages 974-988.
Crossref

Tiziana Vavalà & Silvia Novello. (2018) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology 10, pages 175883591878936.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Articles from other publishers (19)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Citations (19)

Articles from other publishers (19)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date